The following IPOs are expected to price this week:
500.com (WBAI), a leading online sports lottery service provider in China, plans to raise $58 million by offering 5.8 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, 500.com would command a market value of $351 million. 500.com, which was founded in 2001, booked $33 million in sales over the last 12 months. The Shenzhen, China-based company plans to list on the NYSE under the symbol WBAI. Deutsche Bank is the lead bookrunner on the deal.
Evogene (EVGN), which develops genetically enhanced seeds to elevate crop performance and productivity, plans to raise $86 million by offering 5.0 million shares at a price of $17.16. At the midpoint of the proposed range, Evogene would command a market value of $412 million. Evogene, which was founded in 2000, booked $18 million in sales over the last 12 months. The Rehovot, Israel-based company plans to list on the NYSE under the symbol EVGN. Credit Suisse and Deutsche Bank are the joint bookrunners on the deal.
GFI Software (GFIS), which provides collaboration and remote IT management software to small businesses, plans to raise $79 million by offering 6.1 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, GFI Software would command a market value of $557 million. GFI Software, which was founded in 1999, booked $152 million in sales over the last 12 months. The Luxembourg-based company plans to list on the NYSE under the symbol GFIS. J.P. Morgan, Credit Suisse and Jefferies & Co. are the joint bookrunners on the deal.
Navigator Holdings (NVGS), which owns and operates the world's largest fleet of handysize liquefied gas carriers, plans to raise $203 million by offering 11.3 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Navigator Holdings would command a market value of $983 million. Navigator Holdings, which was founded in 1997, booked $207 million in sales over the last 12 months. The London-based company plans to list on the NYSE under the symbol NVGS. Jefferies & Co. and Morgan Stanley are the joint bookrunners on the deal.
Oxford Immunotec Global (OXFD), which sells diagnostic tests for latent tuberculosis infection, plans to raise $75 million by offering 5.4 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Oxford Immunotec Global would command a market value of $247 million. Oxford Immunotec Global, which was founded in 2002, booked $34 million in sales over the last 12 months. The Abingdon, United Kingdom-based company plans to list on the NASDAQ under the symbol OXFD. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal.
Sungy Mobile (GOMO), which provides mobile apps, literary content and entertainment services for Android, plans to raise $74 million by offering 7.0 million shares at a price range of $9.50 to $11.50. At the midpoint of the proposed range, Sungy Mobile would command a market value of $365 million. Sungy Mobile, which was founded in 2003, booked $47 million in sales over the last 12 months. The Guangzhou, China-based company plans to list on the NASDAQ under the symbol GOMO. Credit Suisse and J.P. Morgan are the joint bookrunners on the deal.
TetraLogic Pharmaceuticals (TLOG), which is developing small molecule therapeutics for the treatment of cancer, plans to raise $90 million by offering 6.4 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, TetraLogic Pharmaceuticals would command a market value of $270 million. TetraLogic Pharmaceuticals, which was founded in 2001, booked $0 million in sales over the last 12 months. The Malvern, PA-based company plans to list on the NASDAQ under the symbol TLOG. Oppenheimer & Co., Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal.
Trevena (TRVN), a clinical-stage biotech developing treatments for pain and acute heart failure, plans to raise $75 million by offering 5.8 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Trevena would command a market value of $291 million. Trevena, which was founded in 2007, booked $0 million in sales over the last 12 months. The King of Prussia, PA-based company plans to list on the NASDAQ under the symbol TRVN. Barclays and Jefferies & Co. are the joint bookrunners on the deal.
Vince (VNCE), which designs high-end apparel known for simple styling and luxurious materials, plans to raise $180 million by offering 10.0 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Vince would command a market value of $683 million. Vince, which was founded in 2001, booked $264 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol VNCE. Goldman Sachs, Baird, BofA Merrill Lynch and Barclays are the joint bookrunners on the deal.
Vital Therapies (VTL), a clinical-stage biotech developing treatments for acute liver failure, plans to raise $75 million by offering 4.4 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Vital Therapies would command a market value of $277 million. Vital Therapies, which was founded in 2003, booked $0 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol VTL. Credit Suisse and William Blair are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 8 IPO pricings. zulily (ZU), a flash sales site offering deals on children's apparel and other products for moms, was the week's winner, ending up 71% from its IPO price.
